Mutations in the RAS family (KRAS, NRAS, and HRAS) are well-known drivers of CRC, and KRAS mutations are available in CRC patients at the highest frequency among them (Vogelstein et al., 1988; Kim et al., 2020). The gene discussed is KRAS; the disease is colorectal carcinoma.